

CURRICULUM VITAE

Name Yoon Jun Kim, M. D., Ph. D.

Nationality Korean

Office Address Seoul National University Hospital

101 Daehak-ro, Jongno-gu, Seoul, 110-744, KOREA

Education

- ◇ 1992 (M.D.) Seoul National University (SNU) College of Medicine, Seoul, Korea: graduated *magna cum laude*
- ◇ 1996 (M.S.) Medical Science, SNU Graduate School of Medicine, Seoul, Korea
- ◇ 2001 (Ph.D.) Medical Science, SNU Graduate School of Medicine, Seoul, Korea

Licenses / Certifications

- ◇ Standard License of Medicine, Republic of Korea (1992)
- ◇ Board of Internal Medicine, Republic of Korea (1997)
- ◇ Board of Gastroenterology, Republic of Korea (2001)

Training Experience

- ◇ Medical Internship, Seoul National University Hospital, 1992 - 1993
- ◇ Residency (Internal Medicine), SNU Hospital (1993-1997)
- ◇ Visiting scientist, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA (1999)
- ◇ Research and Clinical Fellow, Gastroenterology Section (Prof. Y. B. Yoon), Department of Internal medicine, SNU College of Medicine (Seoul) (2000-2001). Medical and surgical consultations. Diagnostic and therapeutic endoscopic procedures (including EVL, endoscopic polypectomy and hemostasis with argon plasma and laser). Liver biopsy, PEIT & RFA for Hepatocellular carcinoma

Teaching Experience

- ◇ Clinical Assistant Professor, Department of Internal Medicine, Seoul National University Hospital, 2001 – 2004
- ◇ Visiting Assistant Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center, 2006.12-2008.2
- ◇ Assistant Professor, Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, 2004 – 2008
- ◇ Associate Professor, Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, 2008 – 2013
- ◇ Professor, Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, 2013 – Present

Professional Organization

- ◇ The Korean Association of Internal Medicine
- ◇ The Korean Association for the Study of the Liver
- ◇ The Korean Society of Gastroenterology
- ◇ The Korean Society of Gastrointestinal Endoscopy
- ◇ Director of academic committee of the Korean Liver Cancer Association, 2013- 2014
- ◇ Director of academic committee of the Korean Radioembolization Association, 2013- Present
- ◇ Secretary General of the Korean Liver Cancer Association, 2014 – 2015
- ◇ Editor-in-chief, Experimental and Molecular Hepatology, 2015 - Present

Recent publications

Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence.
Kang SH, Cho H, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yi NJ, Lee KW, Suh KS, Yoon JH.

J Korean Med Sci. 2018 Oct 12;33(45):e283. doi: 10.3346/jkms.2018.33.e283. eCollection 2018 Nov 5.

Prognostic Value of Biochemical Response Models for Primary Biliary Cholangitis and the Additional Role of the Neutrophil-to-Lymphocyte Ratio.

Yoo JJ, Cho EJ, Lee B, Kim SG, Kim YS, Lee YB, Lee JH, Yu SJ, Kim YJ, Yoon JH.
Gut Liver. 2018 Oct 29. doi: 10.5009/gnl18271. [Epub ahead of print]

PI3K δ Is a Therapeutic Target in Hepatocellular Carcinoma.

Ko E, Seo HW, Jung ES, Ju S, Kim BH, Cho H, Kim YJ, Park YM, Kim JS, Jung G.
Hepatology. 2018 Oct 9. doi: 10.1002/hep.30307. [Epub ahead of print]

Feasibility of Boosted Radioembolization for Hepatocellular Carcinoma Larger than 5 cm.

Kim HC, Kim YJ, Lee JH, Suh KS, Chung JW.
J Vasc Interv Radiol. 2018 Oct 4. pii: S1051-0443(18)31326-5. doi: 10.1016/j.jvir.2018.07.002. [Epub ahead of print]

Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up.

Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, Yoon JH.
Cancer Immunol Immunother. 2018 Sep 19. doi: 10.1007/s00262-018-2247-4. [Epub ahead of print]

Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality.

Bin Lee Y, Nam JY, Lee JH, Chang Y, Cho H, Cho YY, Cho EJ, Yu SJ, Kim HY, Lee DH, Lee JM, Hwang SG, Kim YJ, Yoon JH.
Sci Rep. 2018 Sep 12;8(1):13651. doi: 10.1038/s41598-018-31839-y.

A Novel Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure.

Kim JD, Cho EJ, Ahn C, Park SK, Choi JY, Lee HC, Kim DY, Choi MS, Wang HJ, Kim IH, Yeon JE, Seo YS, Tak WY, Kim MY, Lee HJ, Kim YS, Jun DW, Sohn JH, Kwon SY, Park SH, Heo J, Jeong SH, Lee JH, Nakayama N, Mochida S, Ido A, Tsubouchi H, Takikawa H, Shalimar, Acharya SK, Bernal W, O'Grady J, Kim YJ.
Hepatology. 2018 Sep 8. doi: 10.1002/hep.30262. [Epub ahead of print]

Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK.

Lee S, Cho YY, Cho EJ, Yu SJ, Lee JH, Yoon JH, Kim YJ.
Int J Mol Med. 2018 Nov;42(5):2551-2559. doi: 10.3892/ijmm.2018.3807. Epub 2018 Aug 3.

Balloon-Occluded Retrograde Transvenous Obliteration versus Transjugular Intrahepatic Portosystemic Shunt for the Management of Gastric Variceal Bleeding.

Gimm G, Chang Y, Kim HC, Shin A, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ.
Gut Liver. 2018 Sep 21. doi: 10.5009/gnl17515. [Epub ahead of print]

Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study.

Kim HY, Yoo JJ, Oh S, Yu SJ, Kim YJ, Yoon JH, Kim W, Jung YJ, Kim BH, Kim CM, Park JW, Lee JH.
J Med Virol. 2018 Oct;90(10):1593-1603. doi: 10.1002/jmv.25241. Epub 2018 Jul 10.

Transforming growth factor- β decreases side population cells in hepatocellular carcinoma in vitro.

Kim JB, Lee S, Kim HR, Park SY, Lee M, Yoon JH, Kim YJ.
Oncol Lett. 2018 Jun;15(6):8723-8728. doi: 10.3892/ol.2018.8441. Epub 2018 Apr 5.

Assessment of the Surveillance Interval at 1 Year after Curative Treatment in Hepatocellular Carcinoma: Risk Stratification.

Lee M, Chang Y, Oh S, Cho YY, Jung DE, Kim HH, Nam JY, Cho H, Cho EJ, Lee JH, Yu SJ, Yi NJ, Lee KW, Lee DH, Lee JM, Yoon JH, Suh KS, Kim YJ.

Liver Stiffness Measured by Two-Dimensional Shear-Wave Elastography: Prognostic Value after Radiofrequency Ablation for Hepatocellular Carcinoma.

Lee DH, Lee JM, Yoon JH, Kim YJ, Lee JH, Yu SJ, Han JK.
Liver Cancer. 2018 Mar;7(1):65-75.



Multi-platform genomic roadmap of hepatocellular carcinoma: A matter of molecular heterogeneity.

Woo HG, Kim YJ.

Hepatology. 2018 Apr 10. doi: 10.1002/hep.29925. [Epub ahead of print]

Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction.

Chung GE, Lee JH, Lee H, Kim MK, Yim JY, Choi SY, Kim YJ, Yoon JH, Kim D.

Atherosclerosis. 2018 May;272:137-144.

Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study.

Kim HY, Lee DH, Lee JH, Cho YY, Cho EJ, Yu SJ, Kim YJ, Yoon JH.

BMC Cancer. 2018 Mar 20;18(1):307

Prognostic Role of Liver Stiffness Measurements Using Magnetic Resonance Elastography in Patients with Compensated Chronic Liver Disease.

Lee DH, Lee JM, Chang W, Yoon JH, Kim YJ, Lee JH, Yu SJ, Han JK.

Eur Radiol. 2018 Feb 27. doi: 10.1007/s00330-017-5278-x. [Epub ahead of print]

Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization.

Kim JH, Sinn DH, Lee JH, Hyun D, Cho SK, Shin SW, Chang Y, Kim YJ, Yoon JH, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS.

Dig Dis Sci. 2018 Apr;63(4):1062-1071.

A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma.

Lee HW, Lee JM, Yoon JH, Kim YJ, Park JW, Park SJ, Kim SH, Yi NJ, Suh KS.

Ann Surg Treat Res. 2018 Feb;94(2):74-82.

Comparison of switching bipolar ablation with multiple cooled wet electrodes and switching monopolar ablation with separable clustered electrode in treatment of small hepatocellular carcinoma: A randomized controlled trial.

Chang W, Lee JM, Lee DH, Yoon JH, Kim YJ, Yoon JH, Han JK.

PLoS One. 2018 Feb 8;13(2):e0192173.

Yttrium-90 Radioembolization of the Right Inferior Phrenic Artery in 20 Patients with Hepatocellular Carcinoma.

Kim HC, Kim YJ, Paeng JC, Chung JW.

J Vasc Interv Radiol. 2018 Jan 17. pii: S1051-0443(17)30922-3. doi:

Effect of longitudinal changes of body fat on the incidence and regression of nonalcoholic fatty liver disease.

Kim D, Chung GE, Kwak MS, Kim YJ, Yoon JH.

Dig Liver Dis. 2017 Dec 26. pii: S1590-8658(17)31331-2.

A Model for Adaptive Decision Making of "Ablate-and-Wait" Versus Transplantation in Patients With Hepatocellular Carcinoma.

Kim HY, Kim W, Jung YJ, Lee JH, Yu SJ, Kim YJ, Yoon JH, Lee HW, Kim H, Yi NJ, Lee KW, Suh KS.

J Clin Gastroenterol. 2018 Jan 19. doi: 10.1097/MCG.0000000000000981. [Epub ahead of print]

Genetic association of complement component 2 variants with chronic hepatitis B in a Korean population.

Namgoong S, Shin JG, Cheong HS, Kim LH, Kim JO, Seo JY, Shin HD, Kim YJ.

Liver Int. 2017 Dec 28. doi: 10.1111/liv.13675. [Epub ahead of print]

Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry.

Kim H, Yu SJ, Yeo I, Cho YY, Lee DH, Cho Y, Cho EJ, Lee JH, Kim YJ, Lee S, Jun J, Park T, Yoon JH, Kim Y.

Mol Cell Proteomics. 2017 May 26.

Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.

Cho Y, Lee JH, Lee DH, Cho EJ, Yu SJ, Yi NJ, Lee KW, Kim YJ, Yoon JH, Suh KS.
Oncotarget. 2017 May 10.

Sub-Classification of Advance-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib.
Yoo JJ, Chung GE, Lee JH, Nam JY, Chang Y, Lee JM, Lee DH, Kim HY, Cho EJ, Yu SJ, Kim YJ, Yoon JH; Seoul Liver Group..
Cancer Res Treat. 2017 May 15.

Prophylactic Temporary Occlusion of the Cystic Artery Using a Fibered Detachable Coil During 90Y Radioembolization.
Choi JW, Yoo MY, Kim HC, Paeng JC, Kim YJ, Chung JW.
Cardiovasc Intervent Radiol. 2017 May 12.

Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.
Won JK, Yu SJ, Hwang CY, Cho SH, Park SM, Kim K, Choi WM, Cho H, Cho EJ, Lee JH, Lee KB, Kim YJ, Suh KS, Jang JJ,
Kim CY, Yoon JH, Cho KH.
Hepatology. 2017 Apr 25.

Monotherapy with Tenofovir Disoproxil Fumarate for Multiple Drug-Resistant Chronic Hepatitis B: 3-Year Trial.
Lim YS, Lee YS, Gwak GY, Byun KS, Kim YJ, Choi J, An J, Lee HC, Yoo BC, Kwon SY.
Hepatology. 2017 Mar 30.

3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells.
Lee M, Jo A, Lee S, Kim JB, Chang Y, Nam JY, Cho H, Cho YY, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ.
PLoS One. 2017 Mar 31;12(3):e0174271

Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
Chung GE, Cho EJ, Lee JH, Yoo JJ, Lee M, Cho Y, Lee DH, Kim HY, Yu SJ, Kim YJ, Yoon JH, Zoulim F.
Clin Mol Hepatol. 2017 Mar;23(1):66-73.

Targeted Proteomics Predicts a Sustained Complete-Response after Transarterial Chemoembolization and Clinical Outcomes
in Patients with Hepatocellular Carcinoma: A Prospective Cohort Study.
Yu SJ, Kim H, Min H, Sohn A, Cho YY, Yoo JJ, Lee DH, Cho EJ, Lee JH, Gim J, Park T, Kim YJ, Kim CY, Yoon JH, Kim Y.
J Proteome Res. 2017 Mar 3;16(3):1239-1248.

Validation of a Modified Child-Turcotte-Pugh Classification System Utilizing Insulin-Like Growth Factor-1 for Patients with
Hepatocellular Carcinoma in an HBV Endemic Area.
Lee DH, Lee JH, Jung YJ, Gim J, Kim W, Kim BG, Lee KL, Cho Y, Yoo JJ, Lee M, Cho YY, Cho EJ, Yu SJ, Kim YJ, Yoon JH.
PLoS One. 2017 Jan 20;12(1):e0170394.

Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B
Patients.
Nam JY, Lee JH, Kim HY, Kim JE, Lee DH, Chang Y, Cho H, Yoo JJ, Lee M, Cho YY, Cho Y, Cho E, Yu SJ, Kim YJ, Yoon JH.
PLoS One. 2017 Jan 18;12(1):e0166188.

Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse
model.
Lee DH, Nam JY, Chang Y, Cho H, Kang SH, Cho YY, Cho E, Lee JH, Yu SJ, Kim YJ, Yoon JH.
Cancer Biol Ther. 2017 Jan 2;18(1):67-75

Perceived needs for the information communication technology (ICT)-based personalized health management program, and its
association with information provision, health-related quality of life (HRQOL), and decisional conflict in cancer patients.
Sim JA, Chang YJ, Shin A, Noh DY, Han W, Yang HK, Kim YW, Kim YT, Jeong SY, Yoon JH, Kim YJ, Heo D, Kim TY, Oh DY,
Wu HG, Kim HJ, Chie EK, Kang KW, Kim JH, Yun YH.
Psychooncology. 2017 Jan 5.

Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular
Hepatocellular Carcinomas: Six-Month Outcome Analysis.
Lee M, Chung JW, Lee KH, Won JY, Chun HJ, Lee HC, Kim JH, Lee IJ, Hur S, Kim HC, Kim YJ, Kim GM, Joo SM, Oh JS.
J Vasc Interv Radiol. 2017 Apr;28(4):502-512.

Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B.

Cho Y, Sinn DH, Yu SJ, Gwak GY, Kim JH, Yoo YJ, Jun DW, Kim TY, Lee HY, Cho EJ, Lee JH, Kim YJ, Yoon JH.
PLoS One. 2016 Nov 15;11(11):e0165722.

Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016.

Tanaka A, Ma X, Yokosuka O, Weltman M, You H, Amarapurkar DN, Kim YJ, Abbas Z, Payawal DA, Chang ML, Efe C, Ozaslan E, Abe M, Mitchell-Thain R, Zeniya M, Han KH, Vierling JM, Takikawa H.
Hepatol Int. 2016 Nov;10(6):909-915

A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus.

Lim YS, Ahn SH, Lee KS, Paik SW, Lee YJ, Jeong SH, Kim JH, Yoon SK, Yim HJ, Tak WY, Han SY, Yang JC, Mo H, Garrison KL, Gao B, Knox SJ, Pang PS, Kim YJ, Byun KS, Kim YS, Heo J, Han KH.
Hepatol Int. 2016 May 20

Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis.

Cho YY, Lee M, Kim HC, Chung JW, Kim YH, Gwak GY, Bae SH, Kim do Y, Heo J, Kim YJ.
PLoS One. 2016 May 5;11(5):e0154986. doi: 10.1371/journal.pone.0154986. eCollection 2016.

17 β -estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling.

Lee S, Lee M, Kim JB, Jo A, Cho EJ, Yu SJ, Lee JH, Yoon JH, Kim YJ.
Biochem Biophys Res Commun. 2016 May 13;473(4):1247-54. doi: 10.1016/j.bbrc.2016.04.049.

Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma.

Cho Y, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY, Yoon JH.
Dig Dis Sci. 2016 Apr 13. [Epub ahead of print]

Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis.

Yu SJ, Yoon JH, Kim W, Lee JM, Lee YB, Cho Y, Lee DH, Lee M, Yoo JJ, Cho EJ, Lee JH, Kim YJ, Kim CY.
Korean J Intern Med. 2016 Apr 5. doi: 10.3904/kjim.2015.267. [Epub ahead of print]

Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria.

Lee JH, Cho Y, Kim HY, Cho EJ, Lee DH, Yu SJ, Lee JW, Yi NJ, Lee KW, Kim SH, Kim JM, Joh JW, Teperman LW, Park JS, Kim YJ, Suh KS, Yoon JH.
Ann Surg. 2016 May;263(5):842-50. doi: 10.1097/SLA.0000000000001578.

Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.

Cho Y, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ.
Clin Mol Hepatol. 2015 Dec;21(4):358-64. doi: 10.3350/cmh.2015.21.4.358. Epub 2015 Dec 24.

Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43.

Cho Y, Yoon JH, Yoo JJ, Lee M, Lee DH, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY.
Acta Pharm Sin B. 2015 Nov;5(6):544-53. doi: 10.1016/j.apsb.2015.09.004. Epub 2015 Nov 18.

A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma.

Lee JH, Lee Y, Lee M, Heo MK, Song JS, Kim KH, Lee H, Yi NJ, Lee KW, Suh KS, Bae YS, Kim YJ.
Br J Cancer. 2015 Dec 22;113(12):1666-76. doi: 10.1038/bjc.2015.430. Epub 2015 Dec 10.

Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Yu SJ, Kim W, Kim D, Yoon JH, Lee K, Kim JH, Cho EJ, Lee JH, Kim HY, Kim YJ, Kim CY.
Medicine (Baltimore). 2015 Dec;94(48):e2159. doi: 10.1097/MD.0000000000002159.

High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.

Cho Y, Yu SJ, Cho EJ, Lee JH, Kim TM, Heo DS, Kim YJ, Yoon JH.

J Med Virol. 2016 Jun;88(6):1010-7. doi: 10.1002/jmv.24423. Epub 2015 Nov 13.

Sorafenib inhibits cancer side population cells by targeting c-Jun N-terminal kinase signaling.

Kim JB, Lee M, Park SY, Lee S, Kim HR, Lee HS, Yoon JH, Kim YJ.

Mol Med Rep. 2015 Dec;12(6):8247-52. doi: 10.3892/mmr.2015.4422. Epub 2015 Oct 9.

Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma.

Sohn BH, Shim JJ, Kim SB, Jang KY, Kim SM, Kim JH, Hwang JE, Jang HJ, Lee HS, Kim SC, Jeong W, Kim SS, Park ES, Heo J, Kim YJ, Kim DG, Leem SH, Kaseb A, Hassan MM, Cha M, Chu IS, Johnson RL, Park YY, Lee JS.

Clin Cancer Res. 2016 Mar 1;22(5):1256-64. doi: 10.1158/1078-0432.CCR-15-1447. Epub 2015 Oct 12.

Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease.

Kim D, Chung GE, Kwak MS, Seo HB, Kang JH, Kim W, Kim YJ, Yoon JH, Lee HS, Kim CY.

Clin Gastroenterol Hepatol. 2016 Jan;14(1):132-8.e4. doi: 10.1016/j.cgh.2015.07.024. Epub 2015 Jul 27.

Diagnostic and Prognostic Values of Noninvasive Predictors of Portal Hypertension in Patients with Alcoholic Cirrhosis.

Cho EJ, Kim MY, Lee JH, Lee IY, Lim YL, Choi DH, Kim YJ, Yoon JH, Baik SK.

PLoS One. 2015 Jul 21;10(7):e0133935. doi: 10.1371/journal.pone.0133935. eCollection 2015.

Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: characteristics, treatments, and outcomes.

Park Y, Cho Y, Cho EJ, Kim YJ.

Clin Mol Hepatol. 2015 Jun;21(2):150-7. doi: 10.3350/cmh.2015.21.2.150. Epub 2015 Jun 26.

Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B.

Chan HL, Elkhashab M, Trinh H, Tak WY, Ma X, Chuang WL, Kim YJ, Martins EB, Lin L, Dinh P, Charuworn P, Foster GR, Marcellin P.

J Hepatol. 2015 Nov;63(5):1086-92. doi: 10.1016/j.jhep.2015.06.025. Epub 2015 Jul 2.

Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients.

Cho EJ, Lee JH, Cho Y, Lee YB, Yoo JJ, Lee M, Lee DH, Yu SJ, Kim YJ, Yoon JH, Lee HS.

PLoS One. 2015 Jun 29;10(6):e0130392. doi: 10.1371/journal.pone.0130392. eCollection 2015.

Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein.

Yu SJ, Kim YJ.

World J Hepatol. 2015 Jun 18;7(11):1553-61. doi: 10.4254/wjh.v7.i11.1553. Review.

Hepatoprotective effect of vitamin C on lithocholic acid-induced cholestatic liver injury in Gulo(-/-) mice.

Yu SJ, Bae S, Kang JS, Yoon JH, Cho EJ, Lee JH, Kim YJ, Lee WJ, Kim CY, Lee HS.

Eur J Pharmacol. 2015 Sep 5;762:247-55. doi: 10.1016/j.ejphar.2015.06.008. Epub 2015 Jun 6.

Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.

Yoo JJ, Cho EJ, Cho YY, Lee M, Lee DH, Cho Y, Lee JH, Yu SJ, Yoon SS, Yoon JH, Kim YJ.

Liver Int. 2015 Dec;35(12):2530-6. doi: 10.1111/liv.12882. Epub 2015 Jun 19.

Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population.

Kwak MS, Kim D, Chung GE, Kim W, Kim YJ, Yoon JH.

World J Gastroenterol. 2015 May 28;21(20):6287-95. doi: 10.3748/wjg.v21.i20.6287.

Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model.

Kwak MS, Yu SJ, Yoon JH, Lee SH, Lee SM, Lee JH, Kim YJ, Lee HS, Kim CY.

J Cancer Res Clin Oncol. 2015 Nov;141(11):2037-45. doi: 10.1007/s00432-015-1990-6. Epub 2015 May 20.

Replication of genome wide association studies on hepatocellular carcinoma susceptibility loci of STAT4 and HLA-DQ in a

Korean population.

Kim LH, Cheong HS, Namgoong S, Kim JO, Kim JH, Park BL, Cho SW, Park NH, Cheong JY, Koh I, Shin HD, Kim YJ.
Infect Genet Evol. 2015 Jul;33:72-6. doi: 10.1016/j.meegid.2015.04.013. Epub 2015 Apr 22.

Post-treatment intracranial hemorrhage of brain metastases from hepatocellular carcinoma.

Kim KS, Kim K, Chie EK, Kim YJ, Yoon JH, Lee HS, Ha SW.
Radiat Oncol J. 2015 Mar;33(1):36-41. doi: 10.3857/roj.2015.33.1.36. Epub 2015 Mar 31.

Comparison of transarterial chemoembolization and hepatic resection for large solitary hepatocellular carcinoma: a propensity score analysis.

Lee YB, Lee DH, Cho Y, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim HC, Yi NJ, Lee KW, Suh KS, Chung JW, Kim YJ.
J Vasc Interv Radiol. 2015 May;26(5):651-9. doi: 10.1016/j.jvir.2015.02.004. Epub 2015 Mar 29.

Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.

Lim YS, Yoo BC, Byun KS, Kwon SY, Kim YJ, An J, Lee HC, Lee YS.
Gut. 2016 Jun;65(6):1042-51. doi: 10.1136/gutjnl-2014-308435. Epub 2015 Mar 23.

Hepatitis B virus-related glomerulonephritis: not a predominant cause of proteinuria in Korean patients with chronic hepatitis B.

Yoo JJ, Lee JH, Yoon JH, Lee M, Lee DH, Cho Y, Jang ES, Cho EJ, Yu SJ, Kim YJ, Lee HS.
Gastroenterol Res Pract. 2015;2015:126532. doi: 10.1155/2015/126532. Epub 2015 Feb 18.

Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.

Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, Yoon JH.
Gastroenterology. 2015 Jun;148(7):1383-91.e6. doi: 10.1053/j.gastro.2015.02.055. Epub 2015 Mar 4.

The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.

Gane EJ, Lim YS, Gordon SC, Visvanathan K, Sicard E, Fedorak RN, Roberts S, Massetto B, Ye Z, Pflanz S, Garrison KL, Gaggar A, Mani Subramanian G, McHutchison JG, Kottlilil S, Freilich B, Coffin CS, Cheng W, Kim YJ.
J Hepatol. 2015 Aug;63(2):320-8. doi: 10.1016/j.jhep.2015.02.037. Epub 2015 Feb 27.

Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments.

Cho Y, Lee JH, Yu SJ, Yoon JH, Lee HS, Kim YJ.
J Med Virol. 2015 Jun;87(6):999-1007. doi: 10.1002/jmv.24150. Epub 2015 Feb 24.

Reduction of oxidative stress attenuates lipoapoptosis exacerbated by hypoxia in human hepatocytes.

Hwang SY, Yu SJ, Lee JH, Kim HY, Kim YJ.
Int J Mol Sci. 2015 Feb 3;16(2):3323-34. doi: 10.3390/ijms16023323.

The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection.

Lee YB, Lee JH, Kim YJ, Yoon JH, Lee HS.
J Med Virol. 2015 Apr;87(4):575-82. doi: 10.1002/jmv.24091. Epub 2015 Jan 21.

Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.

Lim YS, Byun KS, Yoo BC, Kwon SY, Kim YJ, An J, Lee HC, Lee YS.
Gut. 2016 May;65(5):852-60. doi: 10.1136/gutjnl-2014-308353. Epub 2015 Jan 16.

Forns index predicts recurrence and death in patients with hepatitis B-related hepatocellular carcinoma after curative resection.

Choi WM, Lee JH, Ahn H, Cho H, Cho YY, Lee M, Yoo JJ, Cho Y, Lee DH, Lee YB, Cho EJ, Yu SJ, Yi NJ, Lee KW, Kim YJ, Yoon JH, Suh KS, Kim CY, Lee HS.
Liver Int. 2015 Aug;35(8):1992-2000. doi: 10.1111/liv.12776. Epub 2015 Jan 22.

Occult hepatitis B virus infection.

Kwak MS, Kim YJ.
World J Hepatol. 2014 Dec 27;6(12):860-9.

Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI: risk of HCC recurrence after radiofrequency ablation.

Lee DH, Lee JM, Lee JY, Kim SH, Kim JH, Yoon JH, Kim YJ, Lee JH, Yu SJ, Han JK, Choi BI.
J Hepatol. 2015 May;62(5):1122-30. doi: 10.1016/j.jhep.2014.12.015. Epub 2014 Dec 18.

Transarterial Chemoembolization for Hepatocellular Carcinomas with Central Bile Duct Invasion: Safety, Prognosis, and Predictive Factors.

Choi JW, Chung JW, Cho YK, Kim YJ, Yoon JH, Kim HC, Jae HJ.
Cardiovasc Intervent Radiol. 2015 Aug;38(4):937-45. doi: 10.1007/s00270-014-1032-9. Epub

Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases.

Yoo JJ, Lee JH, Lee SH, Lee M, Lee DH, Cho Y, Lee YB, Yu SJ, Kim HC, Kim YJ, Yoon JH, Kim CY, Lee HS.
PLoS One. 2014 Nov 26;9(11):e113926. doi: 10.1371/journal.pone.0113926. eCollection 2014.

Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B.

Lee YB, Jung EU, Kim BH, Lee JH, Cho H, Ahn H, Choi WM, Cho YY, Lee M, Yoo JJ, Cho Y, Lee DH, Cho EJ, Yu SJ, Park SJ, Kim YJ, Park JW, Lee YJ, Kim CM, Yoon JH, Kim CY, Lee HS.
Antimicrob Agents Chemother. 2015 Feb;59(2):972-8. doi: 10.1128/AAC.04454-14. Epub 2014 Nov 24.

Association of polymorphism in microRNA 604 with susceptibility to persistent hepatitis B virus infection and development of hepatocellular carcinoma.

Cheong JY, Shin HD, Cho SW, Kim YJ.
J Korean Med Sci. 2014 Nov;29(11):1523-7. doi: 10.3346/jkms.2014.29.11.1523. Epub 2014 Nov 4.

Association of VARS2-SFTA2 polymorphisms with the risk of chronic hepatitis B in a Korean population.

Cheong HS, Lee JH, Yu SJ, Yoon JH, Lee HS, Cheong JY, Cho SW, Park NH, Park BL, Namgoong S, Kim LH, Shin HD, Kim YJ.
Liver Int. 2015 Aug;35(8):1934-40. doi: 10.1111/liv.12740. Epub 2015 Jan 10.

JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs.

Kim JB, Park SY, Kim HR, Ahn YH, Jee HG, Lee JH, Yu SJ, Lee HS, Lee M, Yoon JH, Kim YJ.
Mol Med Rep. 2015 Jan;11(1):263-8.

BCLC System Provides the Best Discrimination Ability for Survival of Untreated Hepatocellular Carcinoma Patients in an HBV-endemic Area.

Lee JH, Kim HY, Kim YJ, Yoon JH, Chung JW, Lee HS.
J Gastroenterol Hepatol. 2014 Sep 22.

A novel prognostic factor for hepatocellular carcinoma: protein disulfide isomerase.

Yu SJ, Won JK, Ryu HS, Choi WM, Cho H, Cho EJ, Lee JH, Kim YJ, Suh KS, Jang JJ, Kim CY, Lee HS, Yoon JH, Cho KH.
Korean J Intern Med. 2014 Sep;29(5):580-7.

CLIF-SOFA scoring system accurately predicts short-term mortality in acutely decompensated patients with alcoholic cirrhosis: a retrospective analysis.

Lee M, Lee JH, Oh S, Jang Y, Lee W, Lee HJ, Yoo JJ, Choi WM, Cho YY, Cho Y, Lee DH, Lee YB, Yu SJ, Yi NJ, Lee KW, Kim YJ, Yoon JH, Suh KS, Lee HS.
Liver Int. 2015 Jan;35(1):46-57.

Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains.

Lee YB, Lee JH, Lee DH, Cho H, Ahn H, Choi WM, Cho YY, Lee M, Yoo JJ, Cho Y, Cho EJ, Yu SJ, Kim YJ, Yoon JH, Kim CY, Lee HS.
Antimicrob Agents Chemother. 2014 Nov;58(11):6710-6.

Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma?
Cho Y, Lee DH, Lee YB, Lee M, Yoo JJ, Choi WM, Cho YY, Paeng JC, Kang KW, Chung JK, Yu SJ, Lee JH, Yoon JH, Lee HS,

Kim YJ.

PLoS One. 2014 Aug 25;9(8):e105679.

Prognostic stratification of brain metastases from hepatocellular carcinoma.

Kim KS, Kim K, Chie EK, Kim YJ, Yoon JH, Lee HS, Ha SW.

J Neurooncol. 2014 Oct;120(1):209-14.

Spontaneous evolution in bilirubin levels predicts liver-related mortality in patients with alcoholic hepatitis.

Lee M, Kim W, Choi Y, Kim S, Kim D, Yu SJ, Lee JH, Kim HY, Jung YJ, Kim BG, Kim YJ, Yoon JH, Lee KL, Lee HS.

PLoS One. 2014 Jul 11;9(7):e100870.

Tauroursodeoxycholic acid attenuates progression of steatohepatitis in mice fed a methionine-choline-deficient diet.

Cho EJ, Yoon JH, Kwak MS, Jang ES, Lee JH, Yu SJ, Kim YJ, Kim CY, Lee HS.

Dig Dis Sci. 2014 Jul;59(7):1461-74.

Association of polymorphism in microRNA 604 with susceptibility to persistent hepatitis B virus infection and development of hepatocellular carcinoma.

Cheong JY, Shin HD, Cho SW, Kim YJ.

J Korean Med Sci. 2014 Nov;29(11):1523-7.

JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs.

Kim JB, Park SY, Kim HR, Ahn YH, Jee HG, Lee JH, Yu SJ, Lee HS, Lee M, Yoon JH, Kim YJ.

Mol Med Rep. 2015 Jan;11(1):263-8

BCLC System Provides the Best Discrimination Ability for Survival of Untreated Hepatocellular Carcinoma Patients in an HBV-endemic Area.

Lee JH, Kim HY, Kim YJ, Yoon JH, Chung JW, Lee HS.

J Gastroenterol Hepatol. 2014 Sep 22.

A novel prognostic factor for hepatocellular carcinoma: protein disulfide isomerase.

Yu SJ, Won JK, Ryu HS, Choi WM, Cho H, Cho EJ, Lee JH, Kim YJ, Suh KS, Jang JJ, Kim CY, Lee HS, Yoon JH, Cho KH.

Korean J Intern Med. 2014 Sep;29(5):580-7.

CLIF-SOFA scoring system accurately predicts short-term mortality in acutely decompensated patients with alcoholic cirrhosis: a retrospective analysis.

Lee M, Lee JH, Oh S, Jang Y, Lee W, Lee HJ, Yoo JJ, Choi WM, Cho YY, Cho Y, Lee DH, Lee YB, Yu SJ, Yi NJ, Lee KW, Kim YJ, Yoon JH, Suh KS, Lee HS.

Liver Int. 2015 Jan;35(1):46-57.

Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains.

Lee YB, Lee JH, Lee DH, Cho H, Ahn H, Choi WM, Cho YY, Lee M, Yoo JJ, Cho Y, Cho EJ, Yu SJ, Kim YJ, Yoon JH, Kim CY, Lee HS.

Antimicrob Agents Chemother. 2014 Nov;58(11):6710-6.

Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma?

Cho Y, Lee DH, Lee YB, Lee M, Yoo JJ, Choi WM, Cho YY, Paeng JC, Kang KW, Chung JK, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim YJ.

PLoS One. 2014 Aug 25;9(8):e105679.

Prognostic stratification of brain metastases from hepatocellular carcinoma.

Kim KS, Kim K, Chie EK, Kim YJ, Yoon JH, Lee HS, Ha SW.

J Neurooncol. 2014 Oct;120(1):209-14.

Spontaneous evolution in bilirubin levels predicts liver-related mortality in patients with alcoholic hepatitis.

Lee M, Kim W, Choi Y, Kim S, Kim D, Yu SJ, Lee JH, Kim HY, Jung YJ, Kim BG, Kim YJ, Yoon JH, Lee KL, Lee HS.

PLoS One. 2014 Jul 11;9(7):e100870.

Tauroursodeoxycholic acid attenuates progression of steatohepatitis in mice fed a methionine-choline-deficient diet.
Cho EJ, Yoon JH, Kwak MS, Jang ES, Lee JH, Yu SJ, Kim YJ, Kim CY, Lee HS.
Dig Dis Sci. 2014 Jul;59(7):1461-74.

Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting.
Yang HJ, Lee JH, Lee DH, Yu SJ, Kim YJ, Yoon JH, Kim HC, Lee JM, Chung JW, Yi NJ, Lee KW, Suh KS, Lee HS.
Radiology. 2014 Jun;271(3):909-18.

Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence.
Choi WM, Lee JH, Yoon JH, Kwak C, Lee YJ, Cho YY, Lee YB, Yu SJ, Kim YJ, Kim HH, Kim HC, Cho SY, Lee SB, Jeong H, Kim CY, Lee HS.
Endocr Relat Cancer. 2014 Mar 7;21(2):343-53.

Association of VARS2-SFTA2 polymorphisms with the risk of chronic hepatitis B in a Korean population.
Cheong HS, Lee JH, Yu SJ, Yoon JH, Lee HS, Cheong JY, Cho SW, Park NH, Park BL, Namgoong S, Kim LH, Shin HD, Kim YJ.
Liver Int. 2014 Nov 18.

Association of a microRNA-323b polymorphism with the persistence of hepatitis B virus infection by the enhancement of viral replication.
Yu SJ, Kim JW, Lee JH, Yoon JH, Lee HS, Cheong JY, Cho SW, Shin HD, Kim YJ.
J Viral Hepat. 2014 Dec;21(12):853-9.

MicroRNA-196A-2 polymorphisms and hepatocellular carcinoma in patients with chronic hepatitis B.
Kim HY, Yoon JH, Lee HS, Cheong JY, Cho SW, Shin HD, Kim YJ.
J Med Virol. 2014 Mar;86(3):446-53.

Lee JH, Cho Y, Lee DH, Lee M, Yoo JJ, Choi WM, Cho YY, Lee YB, Yu SJ, Yoon JH, Lee HS, Kim YJ.
Prior exposure to lamivudine increases entecavir-resistance risk in chronic hepatitis B patients without detectable lamivudine-resistance.
Antimicrob Agents Chemother. 2014 Jan 6. [Epub ahead of print]

Jang ES, Yoon JH, Lee SH, Lee SM, Lee JH, Yu SJ, Kim YJ, Lee HS, Kim CY.
Sodium taurocholate cotransporting polypeptide mediates dual actions of deoxycholic acid in human hepatocellular carcinoma cells: enhanced apoptosis versus growth stimulation.
J Cancer Res Clin Oncol. 2014 Jan;140(1):133-44. doi: 10.1007/s00432-013-1554-6. Epub 2013 Nov 27.